Molecular docking, ADME and toxicity study of some chemical and natural plant based drugs against COVID-19 main protease
by Kaushik Sarkar; Rajesh Kumar Das
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 14, No. 1, 2021

Abstract: In view of the non-availability of any secure vaccine for COVID-19 caused by SARS-CoV-2, scientists around the world have been running to develop potential inhibitors against SARS-CoV-2. The present study helps us to identify and screen best phytochemicals (chemical drugs or plant based compounds) as potent inhibitors against COVID-19. In this study, we have measured the virtual interactions of COVID-19 main protease (PDB: 6LU7) with lung cancer, bronchitis and blood thinner drugs as well as some natural plant based compounds. Best docking results have been considered on the basis of disulfiram, tideglusib and shikonin. Absorption, distribution, metabolism and excretion (ADME) and toxicity are also predicted for these compounds. From this study, we will expect these drugs to undergo validation in human clinical trials to use as promising candidates for antiviral treatment with high potential to fight against COVID-19.

Online publication date: Thu, 08-Apr-2021

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?


Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com